677 related articles for article (PubMed ID: 18707846)
1. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
[TBL] [Abstract][Full Text] [Related]
2. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
[TBL] [Abstract][Full Text] [Related]
3. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
[TBL] [Abstract][Full Text] [Related]
4. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
5. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
[TBL] [Abstract][Full Text] [Related]
6. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
[TBL] [Abstract][Full Text] [Related]
8. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
[TBL] [Abstract][Full Text] [Related]
9. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
10. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
[TBL] [Abstract][Full Text] [Related]
11. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
12. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
[TBL] [Abstract][Full Text] [Related]
13. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.
Kim WU; Yoo WH; Park W; Kang YM; Kim SI; Park JH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY
J Rheumatol; 2000 Mar; 27(3):575-81. PubMed ID: 10743792
[TBL] [Abstract][Full Text] [Related]
14. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
[TBL] [Abstract][Full Text] [Related]
15. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
[TBL] [Abstract][Full Text] [Related]
16. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
Marotte H; Maslinski W; Miossec P
Arthritis Res Ther; 2005; 7(1):R149-55. PubMed ID: 15642135
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
20. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
